Research programme: anti-fibrotics - Shire

Drug Profile

Research programme: anti-fibrotics - Shire

Alternative Names: FT-01; FT-026; FT-061; FT-071; SHP-628; Tranilast analogues - Shire

Latest Information Update: 13 May 2014

Price : $50

At a glance

  • Originator Fibrotech Therapeutics; University of Melbourne
  • Developer Shire
  • Class Anthranilic acids; Halogenated hydrocarbons; Small molecules
  • Mechanism of Action Collagen inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Arthritis; Chronic heart failure; Kidney disorders; Pulmonary fibrosis

Most Recent Events

  • 02 May 2014 Shire acquires Fibrotech Therapeutics
  • 12 Mar 2014 Preclinical trials in Kidney disorders in Australia (unspecified route)
  • 12 Mar 2014 Preclinical trials in Pulmonary fibrosis in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top